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Objective Management of outbreaks of pneumonia due to Legionella pneumophila serogroup 1 (SG1) infection
requires rapid and accurate diagnostic tests. Current serologic approaches, based on detection of seroconversion
for total antibody, do not fulfil this requirement.
Methods A diagnostic test based on detection of IgM antibody to L. pneumophila SG1 by indirect
immunofluorescence was developed and used to evaluate serum samples from patients involved in a community
outbreak of L. pneumophila SG1 pneumonia that occurred in Spain.
Results Testing of samples from serologically proven, sporadic cases of pneumonia due to L. pneumophila SG1
(14), cases of atypical pneumonia due to other infectious agents (16) and healthy controls (100) supported the
sensitivity and specificity of the assay. On samples from the outbreak, the IgM assay recognized five of six cases
with isolation of L. pneumophila SG1 from respiratory secretions or lung tissue and more than 70% of cases
with confirmed or presumptive diagnosis as determined by the current serologic criteria. In addition, the IgM
assay was positive in 23–70% of patients who fulfilled the clinical and epidemiologic criteria of case definition
but did not display diagnostically significant serologic results or who lacked a detectable antibody response in
the routine assay. Among cases confirmed by the current criteria, detection of specific IgM was occasionally
achieved before the conventional serology gave significant results.
Conclusions Incorporation of IgM antibody detection in the current diagnostic criteria for L. pneumophila
SG1 infection may help to improve the management of outbreaks of pneumonia due to this agent.
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INTRODUCTION
The management of outbreaks of pneumonia due to Legionella
pneumophila serogroup 1 (SG1) requires a rapid and accurate
diagnosis of early cases. Such diagnosis has routinely been done
by serology [1]. Because of the stringent culture requirements of
L. pneumophila, diagnosis by bacterial isolation from respiratory
secretions, lung tissue or blood is rarely achieved. In recent
years, detection of L. pneumophila soluble antigens in urine by
enzyme immunoassay (EIA) (antigenuria test) has been
developed and is under evaluation as a new diagnostic approach
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which could reach up to 80% sensitivity in cases proven by
bacterial isolation [2].
Serologic diagnosis of L. pneumophila SG1 infections is
achieved by titration of total antibody by indirect immuno-
fluorescence (IIF) on paired serum samples. Seroconversion or
a four-fold rise in titer are taken as the main diagnostic criteria
[1]. In both cases, antibody must reach a titer of 128 or above
for the results to be considered significant. When no sero-
conversion or rise in titer is documented or paired serum sam-
ples are not available, a single titer of 256 is considered to be
presumptive. Definition of these criteria helps to avoid false-
positive diagnoses due to cross-reacting antibody responses to
other pathogens. In practice, the percentage of epidemio-
logically confirmed cases of L. pneumophila outbreak-associated
pneumonias fulfilling these criteria is less than 50% [3,4]. More-
over, the antibody response may take several weeks to reach
diagnostically significant levels, thereby delaying confirmation
of the diagnosis.
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Detection of specific IgM in serum is a widely used approach
for the serologic diagnosis of many acute primary infections and
has been used to evaluate patients with L. pneumophila infection
[5]. For many infectious agents, IgM detection behaves as an
early and sensitive diagnostic marker that may provide the
diagnosis several days, or even weeks, before the IgG antibody
response reaches significant levels. We have developed an IIF
assay to detect IgM antibody to L. pneumophila SG1 in serum
and used this assay to study serum samples of patients from a




IgM antibodies to L. pneumophila SG1 were studied in serum
samples from patients from a community outbreak of pneu-
monia that occurred in the city of Alcala´ de Henares (Auton-
omous Region of Madrid, Spain) during August and September
1996. All patients included as cases in the outbreak had to satisfy
two major clinical criteria (presence of pulmonary infiltrate on
radiologic examination and onset of disease less than 10 days
before admission) and display at least three of the following
four groups of signs or symptoms: (1) fever; (2) general malaise,
arthromyalgias or headache; (3) respiratory symptoms including
cough, dyspnea or pleuritic chest pain; (4) an alveolar arterial
gradient higher than 20 mmHg. Residency in the northern
districts of Alcala´ de Henares or having visited such districts
within 3 weeks prior to admission were used as epidemiologic
criteria for inclusion. Exclusion of patients meeting these clini-
cal and epidemiologic criteria was based on the following find-
ings: detection of tuberculosis by direct stain of the sputum;
isolation of bacteria other than Legionella from blood, pleural
fluid or bronchial secretions; and diagnosis of any other con-
dition that may account for the clinical symptoms [6].
Analysis was performed on the following groups of samples:
1. Serial samples (106) from 48 patients with seroconversion
to L. pneumophila SG1 total antibody by IIF (see below),
with at least a follow-up sample giving an antibody titer
128 (confirmed cases).
2. Single or serial samples (59) from 37 patients with no sero-
conversion documented but showing an antibody titer
256 in one or more samples (presumptive cases).
3. Serial samples (29) from 10 patients with seroconversion to
an antibody titer of 64 on follow-up (seroconversion to low
titer).
4. Single or serial samples (52) from 31 patients with no sero-
conversion documented but showing an antibody titer of
64 or 128 (single low titer).
5. Paired samples (52) taken during the first and fourth weeks
after the onset of pneumonia from 26 patients without
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detectable antibody response (titer 64) (no antibody
response).
Only patients from the former two groups could be considered
as confirmed or presumptive cases according to the current
serologic criteria for confirmation. In six patients (two from
group 1, two from group 2, one from group 3 and one from
group 5), L. pneumophila SG1, subgroup Pontiac, minor sub-
group Knoxville was isolated from respiratory secretions or lung
tissue [6]. As well as IgM to L. pneumophila SG1, antibodies
to Mycoplasma pneumoniae, Coxiella burnetii, Chlamydia psittaci,
influenza A and B viruses, adenovirus and respiratory syncytial
virus (RSV) were studied by complement fixation test (CFT),
using a standard procedure [7].
To validate the IgM assay, a group of serum samples was
studied, including: (1) samples from 16 patients with pneu-
monia due to influenza A virus (n = 3), RSV (n = l), M. pneu-
moniae (n = 4), Coxiella burnetii (n = 2) and Chlamydia psittaci
(n = 1), diagnosed by seroconversion (CFT antibody), and
Streptococcus pneumoniae (n = 5, serotypes 3, 4, 8, 14 and 23) as
diagnosed by bacterial isolation; (2) paired samples from 14
sporadic cases of pneumonia due to L. pneumophila SG1 diag-
nosed by seroconversion in the IIF test; and (3) 100 samples
from normal individuals living in the Autonomous Region of
Madrid aged 41–60 years old.
Antibody tests to Legionella pneumophila SG1
Total antibodies to L. pneumophila SGI were titrated by IIF [8].
Heat-inactivated L. pneumophila SG1 Philadelphia strain grown
in BCYE and resuspended in 0.5% normal yolk sac (NYS),
phosphate-buffered saline (PBS) solution was used as antigen.
Pretitered fluorescein isothiocyanate (FITC)-conjugated, rabbit
antihuman (IgG + IgM + IgA) antibody (Dako, Denmark) was
used as the conjugate. Samples were diluted 1/16 in NYS–
PBS and two-fold serial dilutions (from 1/16 to 1/2048) were
prepared and tested by IIF The antibody titer was determined
as the highest serum dilution giving a fluorescence pattern
similar to the endpoint dilution of an L. pneumophila SG1-
specific positive control serum (titer 1/1024) that was included
in each IIF run. Samples were tested under code, so the readers
were blinded with respect to clinical history or prior laboratory
results. Only titers 1/64 were considered and recorded as
positive.
IgM antibody to L. pneumophila SG1 was investigated by
IIF, using the same antigen as above. Briefly, 50 mL of pre-
diluted (l/10) serum was mixed with 50 mL of sheep antihuman
IgG serum (RF Absorbens, Behring Institute, Marburg, Ger-
many) and incubated for 15 min at room temperature. After
centrifugation at 3000 g for 5 min, the supernatant (dilution
1/20 of the original sample) was layered onto antigen-coated
wells from two identical slides. One slide was incubated for
90 min at 37 °C and used for IgM detection; and the second
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slide was incubated for 30 min at the same temperature and
used to assess the removal of specific IgG. After such incu-
bations, slides were washed twice with PBS for 5 min and
then air-dried. Antihuman IgM or IgG antibody (rabbit)–FITC
conjugated (Dako, Copenhagen, Denmark) was then added to
each respective slide and incubated for 30 min at 37 °C. Slides
were washed again as above and fluorescence was evaluated
under  200 magnification in an epifluorescence microscope.
The presence of specific IgM was considered in samples positive
in the IgM slide and negative in the IgG slide.
RESULTS
Validation of the IgM assay
All samples from patients with pneumonia due to agents other
than L. pneumophila were negative in the IgM assay. Among
sporadic cases of serologically proven pneumonia by L. pneu-
mophila SG1, IgM antibodies were detected in 11 cases (78.6%).
Among normal individuals, two positive samples were found
(prevalence rate: 2%).
Testing of samples from the outbreak
A summary of the results obtained on samples from the pneu-
monia outbreak in Alcala´ de Henares is given in Table 1. Posi-
tive results for IgM were obtained in 68.8% of confirmed cases
(group 1) and 78.4% of presumptive cases (group 2). Moreover,
IgM antibody was detected in 70% of cases with seroconversion
to low antibody titer (group 3), 35.5% of those with low
single titer (group 4) and 23.1% of cases with no total antibody
response (group 5). Five of the six patients with isolation of L.
pneumophila SG1 from respiratory secretions or lung tissue were
positive for specific IgM (Table 2).
During the first week after the onset of pneumonia, most
confirmed cases were negative for IgM, but 37.5% of pre-
sumptive cases and 16.7% of those with single low titers were
positive (Figure 1). During the next 2 weeks, the percentages
rose in all patient’s groups and 23.1% of cases with no antibody
Table 1 Detection of specific IgM in samples from 152 patients from an outbreak of pneumonia due to L. pneumophila SG1
fulfilling the clinical and epidemiologic criteria used for case definition
Patient’s Positive IgM
group Total antibody by IIF Classification Number of cases test (n, %)
1 Sc to 128 Confirmed 48 33 (68.8)
2 Titer 256 (no Sc) Presumptive 37 29 (78.4)
3 Sc to 64 Sc to low titer 10 7 (70)
4 Titer 64–128 (no Sc) Low titer 31 11 (35.5)
5 64 No response 26 6 (23.1)
Sc, seroconversion.
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response by IIF studied at that time were positive for specific
IgM.
DISCUSSION
Investigation of outbreaks of pneumonia by L. pneumophila
SG1 requires rapid and sensitive assays which may provide the
diagnosis of early cases. The most usual diagnostic approach,
based on detection of seroconversion to L. pneumophila SG1 by
IIF assays for total antibody, does not fulfil this requirement.
Detection of specific IgM antibody to L. pneumophila SG1 by
IIF has been used to investigate samples from a wide community
outbreak of L. pneumophila SG1 pneumonia and found to be
helpful in the diagnosis. Among six cases with L. pneumophila
SG1 isolated from respiratory secretions or lung tissue [6], five
were positive for specific IgM and one of these was persistently
negative for total antibody by IIF in three samples taken from
4 to 71 days after the start of pneumonia. Among patients with a
confirmed or presumptive diagnosis established by conventional
serology the IgM assay yielded positive results in more than
70% of cases. This figure is in agreement with the 78.6% of
IgM-positive results found among sporadic cases of serologically
proven L. pneumophila SG1 pneumonia.
Cross-reactivity between Legionella and other micro-
organisms (Campylobacter spp., Rickettsia spp., Proteus spp. and
M. pneumoniae) has been described [8–11] and these findings
have influenced the definition of the currently used criteria for
the diagnosis of L. pneumophila SG1 infections by serology. It
is well known, however, that less than 50% of the epidemio-
logically related L. pneumophila outbreak-associated cases of
pneumonia fulfill such criteria [3,4]. Our results obtained on
samples from patients with pneumonia due to M. pneumoniae,
Coxiella burnetii, Chlamydia psittaci, S. pneumoniae and respiratory
viruses suggest that the L. pneumophila SG 1 IgM assay used in
this investigation has no significant cross-reactivity with anti-
body to the main etiologic agents of community-acquired
pneumonia in Spain [12]. Most reports dealing with serologic
cross-reactivity between L. pneumophila and other bacteria refer
to Campylobacter jejuni and suggest that specific diagnosis of
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Table 2 Total antibody titers and specific IgM in samples from six patients from an outbreak of L. pneumophila SG1 subgroup
Pontiac/Knoxville with the agent isolated from respiratory samples
L. pneumophila isolated from:
Case number (days after onset) Days after onset IIF titer IIF IgM
22 Lung tissuea (9) 2 256 Negative
94 Sputum (10) 7 64 Negative
23 64 Positive
43 64 Negative
187 BAL (15) 15 512 Positive
190 BA (2) 5 64 Negative
48 512 Positive
202 BAL, BA (10) 12 64 Negative
30 1024 Positive
299 BA (1) 4 64 Positive
34 64 Positive
71 64 Positive
a Died 9 days after onset.
BAL, bronchoalveolar lavage; BA, bronchoaspirate.
Figure 1 Timing of the IgM antibody response measured by IIF among the 152 patients with pneumonia included in Table 1. Groups: 1,
confirmed; 2, presumptive; 3, seroconversion to low titer; 4, low titer, no, seroconversion; 5, no response.
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infection with this agent should be performed in patients with
diarrhea and positive antibody tests for L. pneumophila [9]. Such
cross-reactivity was not tested with our L. pneumophila IgM
antibody assay, but as only 4% of the patients involved in the
outbreak of pneumonia reported a diarrheal episode [6], it
seems unlikely that cross-reactivity with Campylobacter jejuni
influenced these results.
The IgM assay gave positive results in a significant pro-
portion (24 of 67, 35.8%) of patients with pneumonia who
satisfied the clinical and epidemiologic criteria for inclusion in
the outbreak but not the current serologic criteria for diagnosis
of L. pneumophila infection. The prevalence of positive results
in the IgM assay found in a healthy population of similar age
range and from the same geographical area was only 2%. Thus,
our results are unlikely to reflect non-specific reactivities or
prior infections by L. pneumophila SG1 but are likely to represent
the potential of this method to diagnose L. pneumophila SG1
acute infections in patients who do not respond with total
antibody at the level required by the current diagnostic criteria.
The results obtained in this study also show the limitations
of the IgM assay in the diagnosis of L. pneumophila SG1. Among
cases with seroconversion for total antibody (group 1), IgM was
generally detected late during follow-up, thus impairing the use
of the test as an early diagnostic marker. The negative results
obtained on early serum samples from five patients with L.
pneumophila SG1 isolated from lung tissue or respiratory
secretions confirm this conclusion. On the other hand, the
majority of the results correspond to patients infected during a
single outbreak due to a single L. pneumophila SG1 strain, and
further studies should be done to confirm the ability of the
assay to identify cases produced by other strains. However, the
finding of positive results in a significant proportion of patients
from the outbreak who did not satisfy the current diagnostic
criteria but showed a clear clinical and epidemiologic relation
with the epidemic episode warrants further evaluation of the
test as a helpful tool for the study of future outbreaks of L.
pneumophila infection.
In conclusion, the IgM assay for L. pneumophila SG1 used
in this study has shown a potential ability to improve the
investigation of outbreaks of pneumonia due to this agent.
Future studies could justify the inclusion of the detection of
specific IgM among the current diagnostic criteria for serologic
diagnosis of L. pneumophila SG1 infections, especially when
cases occur as outbreaks of community-acquired pneumonia.
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